Cancer, this one ailment has made millions of people in the USA suffer and continues to wreak havoc in the lives of thousands of people every year. It is estimated that approximately 40% of Americans are likely to get cancer at some stage in their life. While people have actively started living an active and healthy lifestyle, sometimes this is not enough. Genetic markers along with various environmental factors can lead to even the most careful people getting afflicted with this illness. There is hope though as a few companies such as Tempus, work on a continual basis to ensure that the medical sector gets access to futuristic technology that can help them win the battle against cancer.
Tempus is led by Eric Lefkofsky, and as the co-founder of this foundation, he and his team are in charge of building data enabled precision devices that can help with early diagnosis and accurate treatments for cancer. The tools that are being built by Eric Lefkofsky and his team that can input, calculate, correlate data and provides practical solutions for the American health industry.
The units built by Tempus changed the way data is collected, computed and transformed into usable information. The platform that has been designed by Eric Lefkofsky and his team computes a patient’s clinical data as well as any available molecule data. While there were many challenges faced by Tempus to get access to actual data of patients, these obstacles were slowly and steadily overcome. After gaining access to data, the next challenged faced by this firm was to compute the data so that usable information could be acquired. Since information about patients was available through various sources not limited to doctor’s notes and progress notes, Eric Lefkofsky and his team created a software program that could read large chunks of information while keeping specific considerations in mind. Both language processing and optical character recognition capabilities were built into the software which made it both efficient and reliable.
After putting in years of efforts in further perfecting the system, it is now possible for information related to genomes along with other genetic markers to be calculated using the Data Enabled Precision Machines created by Eric Lefkofsky and his team.
Eric Lefkofsky started his journey in his battle against cancer when his wife was diagnosed with breast cancer. Due to his first-hand experience, being a caretaker for a cancer patient he noticed the large gap between the processes of collecting data and computing it to get usable results. The personal struggle inspired him to build a system that is effective and provides concise solutions that can be used to formulate technologically advanced treatment plans.
In 2006, Eric Lefkofsky founded the Lefkofsky Family Foundation. This trust is charitable and is aimed at creating high impact techniques to improve the lives of people who are affected by Cancer. Both Eric Lefkofsky and his wife Liz believe in their cause and are dedicated to improving the lives of millions of cancer patients in the years to come.
Dr. David Samadi holds the job title Chief of Robotic Surgery. He is the Chief of Robotic Surgery at Lenox Hill Hospital. Iran was where this doctor was born and Persia is where this doctor grew up. During the Iranian Revolution he was forced out of a home and separated from his parents. The situation did not cause him to lose hope and determination. Early on in life he had the desire to endeavor into the medical space to help individuals. He had established a clear idea of where he wanted to go with his profession after watching a prostate carcinoma procedure. He has performed more than 7,000 prostate procedures during his career. After becoming an expert in prostate procedures he became very mesmerized with mechanical procedures. Dr. David Samadi primarily identifies and treats men that are dealing with prostate associated cancer.
Dr. David Samadi’s top priority is to provide excellent outcomes when surgery has been done. He also talks to others about alternative prescriptions and innovative findings in the medical industry.
Dr. David Samadi’s educational background started after fleeing a politically dreadful circumstance. After fleeing such a circumstance he continued his learning abroad. During high school he learned at numerous schools located in United States, Belgium, and London. Eventually, he resided in United States and attended Stony Brook School of Medicine. He graduated with a biochemistry degree. After Stony Brook School of Medicine he attended Montefiore Medical Center and Albert Einstein College of Medicine.
Dr. David Samadi began his journey at Columbia Presbyterian Hospital. He continued his career at Mt. Sinai School of Medicine in the year 2007. At Mt. Sinai School of Medicine he took on a position in the Department of Urology. During his career at Mt. Sinai School of Medicine he also was part of Robotics and Minimally Invasive Surgery. In the year 2013 him and his team moved to Lenox Hill Hospital. His title at Lenox Hill Hospital is Chief of Robotic Surgery.
Dr. David Samadi has been associated with research during his career. He has been noted for groundbreaking and beneficial research. He is involved with research that is associated with the newest therapeutic technologies and unconventional medicine. He is involved with research that has to do with the health aspect of men. Overall, Dr. David Samadi has brought forth impressive research.
In conclusion, Dr. David Samadi is a hardworking, determined, and intelligent individual.
Dr. David Samad’s Social Media: www.facebook.com/DrDavidSamadi/
Dr. Mark Holterman is a pediatric surgeon at OSF Healthcare. He has been at OSF since 2011. He is a faculty member at the University of Illinois College of Medicine in Peoria. Dr. Holterman serves as CEO of Mariam Global Health. He was awarded the Innovative Research Award from the American Diabetes Association. Holterman is one of the co-founders of the Alliance for the Advancement of Cellular Therapies (AACT). He along with his colleagues are supporters of the International Pediatric Specialists Alliance for the Children of Vietnam (IPSAC-VN). Dr. Holterman is a member of the American Pediatric Surgical Association (APSA). Throughout his 30 years in the medical field, he has done many investigations in stem cell therapy, obesity, and autoimmune diseases (i.e. rheumatoid arthritis, psoriasis, Hashimoto’s disease). Visit linkedin.com to view Dr. Mark Holterman’s profile.
Dr. Holterman is the founding CEO of AMARI International. He served as a research associate for the Clinical Research Institute of Montreal from August 1995 to June 1997.
Dr. Mark Holterman belongs to the American College of Surgeons (ACS) and the American Academy of Pediatrics (AAP). He completed his undergraduate education at Yale University, where he studied biology. Holterman graduated with honors. He got his doctor in philosophy and medical degree at the University of Virginia. Dr. Holterman was a general surgery resident at the University of Virginia Health Sciences. He was a surgery instructor and fellow in pediatric surgery at the Seattle Children’s Hospital. Holterman used to be chief surgeon at Advocate Christ Children’s Hospital. Dr. Mark Holterman was a staff pediatric surgeon at Rush University Hospital. Read more at Vitals to know more about Dr. Mark Holterman.
Some of Dr. Holterman’s hospital affiliations are Advocate Illinois Masonic Medical Center, Loyola University Medical Center, and St. Alexius Medical Center. He has two offices: Maywood and Peoria. Holterman has been one of America’s Top Doctors in the following years: 2008, 2010, 2011, 2012, 2013, 2014, 2015, and 2017. The Patient’s Choice Award was awarded to Dr. Mark Holterman in 2012, 2014, and 2015. Holterman received the On-Time Doctor Award for two consecutive years (i.e. 2014 and 2015). He has been received recognition for being a compassionate doctor in 2012, 2014, and 2015.
If you’re not familiar with Cancer Research then you may not know who Clay Siegall is. If you’re well in-tuned with Cancer Research then you definitely who this man is. Dr. Clay Siegall plays a critical role in the fight against this deadly disease known as cancer. He is the President, CEO, and Founder for one of the leading biotechnology organizations in the world. Seattle Genetics is that organization and it redefining cancer research by saving lives. Dr. Siegall has been in the industry for many decades and he has become well respected throughout the industry thanks to his extensive resume. The guy has literally worked with the biggest of names such as Bristol Myers Squibb, The National Institute of Health, and The National Cancer Institute. He has strong passion for he does and has built himself up into a living legend.
Seattle Genetic specializes in the development and commercialization of antibody based therapies. These therapies are far superior than it’s predecessors because of their capabilities. Antibody Drug Conjugates are the weapon of choice and this organization produces them very well. These medications deliver a cell killing shot of agents right into cancerous cells within the body without harming any good cells. Dr. Clay Siegall has entered these medications into multiple strategic licensed deals with GlaxoSmithKline, Genentech, and Pfizer. Now the powerful medications can be used in other countries, 65 countries worldwide to be exact. Hundreds of millions of dollars have been racked up in the U.S. and Canada alone and as of today, the medications have brought in around $325 Million. Thanks to Dr. Siegall’s brilliant way of thinking, he has forced the growth of Seattle Genetics by means of rigorous research, scientific innovation, and drug development. This is the blueprint of success that also happens to be Clay Siegall’s main principles.
Having written up to 70 publications, the current holder of 15 patents, and with the heart of gold, Dr. Clay Siegall has become a modern day living legend.
Maggie Gill has always been seen as one of the most innovative leaders in the U.S. healthcare industry for the work she has completed in the southeast of the country from Florida to Georgia and into areas of South Carolina. After beginning her career as a healthcare financial specialist in Florida, Maggie Gill has found a home at the impressive not for profit Memorial University Medical Center; now working as both the President and CEO of Memorial, Gill has recently been named to the “Hospital Review” list of 135 Nonprofit Hospital and Healthcare Industry CEO’s to watch.
In terms of her work as a healthcare professional, Maggie Gill has spent much of the last few years looking for better ways to aid patients of all ages who fall under the care of Memorial from its Savannah, Georgia base. The latest innovation taken by Maggie Gill and her colleagues at Memorial is the decision to make a great investment in preventative care for Medicare Advantage program recipients in the latest partnership between Memorial and Eon Health, a well known Medicare specialist insurance provider based in Georgia and South Carolina.
Alongside a range of options for receiving low cost care in a number of areas in Georgia and the Low Country of South Carolina, Eon and Memorial have come together in a bid to inspire Medicare recipients to live a more active and healthy lifestyle. Maggie Gill believes this is an important factor in helping an aging population who may not be looking to take advantage of the latest options in preventative care for themselves. Part of the Medicare Advantage Plan that began enrollment in January 2017 that has been heavily discussed is the access to Silver Sneakers fitness programs and information made readily available about how to live a healthy lifestyle.